Wei Pang

TL;DR: It is demonstrated that neutralizing antibodies generated from the primary infection could protect the Rhesus macaques from a second-round challenge by SARS-CoV-2, and the non-human primate model that is established here provides a valuable platform to study Sars-Co V-2 pathogenesis and to evaluate candidate vaccines and therapeutics.

TL;DR: The current status of NHPs in China and other areas is covered, highlighting the latest developments in disease models using NHPs, as well as outlining basic problems and proposing effective countermeasures to better utilize NHP resources and further foster NHP research in China.

TL;DR: In the past years, large numbers of promising fusion inhibitory peptides have emerged and some of these new compounds have great potential to be further developed as therapeutic agents.

TL;DR: The research encouraged potent gelatinase inhibitors might be used in the development of anti-HIV-1 agents, especially compounds 4m and 7h, which gave enhanced gelatinase inhibition in comparison with the positive control LY52, and also decentAnti-Hiv-1 potencies.

TL;DR: The results suggested that CD24Fc confers protection to SIV‐infected ChRMs against progression to AIDS, and it was implied that CD 24Fc may be a potential therapeutic approach for the control of HIV‐1/AIDS.